Dr. Alysa Robin Herman, MD

Dr. Herman practices at Skin and Cancer Associates in Coral Gables, Florida.

Dr. Herman's NPI, 1245235829, was assigned on June 20, 2005. Dr. Herman graduated from Boston University School Of Medicine in 1999. Dr. Herman holds Florida license ME89408.

Dr. Herman's primary practice is Skin and Cancer Associates, at 135 San Lorenzo Ave, Coral Gables, FL 33146 in Miami-Dade County. The practice phone is (954) 473-6750.

Dr. Herman's primary practice is Skin and Cancer Associates in Coral Gables, Florida. The medical group on file is Alysa Herman. Dmand AI also links Dr. Herman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Herman practices. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Herman's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Herman is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Herman's licenses on file in 3 states: Florida, California and New York.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, rash, scalp rash, skin cyst and skin discoloration among the conditions Dr. Herman treats.

CMS data shows 4,179 Medicare services from Dr. Herman across 27 procedure codes in 2024, for 704 Medicare patients. Medicare paid $858,169 for them. Every service was in an office.

CMS counts 704 Medicare patients who saw Dr. Herman in 2024. The largest group is 75 to 84, with 320 patients. 75% of them have high cholesterol, and 66% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Herman's median patient age at 63, with 49% women.

In 2024, Dr. Herman wrote 133 Medicare Part D claims for 94 patients. 97% of them were for generic drugs. CMS names the drug for 93 of them, across 5 drugs with 11 or more claims each, at $1,508 in total drug cost. In 2023, CMS named 96 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Herman for performance year 2024, reported individually. Dr. Herman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 190 procedures of melanoma (skin cancer) excision by Dr. Herman, more than 97% of the clinicians it reports for that procedure.

Dmand AI links 6 papers to Dr. Herman in 2010. The most frequent topics are Skin Neoplasms and Facial Neoplasms. Dr. Herman has published most often in Dermatol Surg. Dr. Herman's most frequent co-authors are Cheryl Aber, MD, Daniel Berg, MD and Ashish C. Bhatia, MD.

CMS Open Payments shows 5 general payments to Dr. Herman from 4 drug and device companies from 2018 to 2022. Food and beverage make up the largest share, 100% of the total. Sun Pharmaceutical Industries Inc. paid the most, $31.

Dmand AI lists 3 awards for Dr. Herman, most recently CMS Stage 1 EHR in 2013.

Dr. Herman graduated from Boston University School Of Medicine in 1999. Dr. Herman is a member of AAD and ASDS.

Dr. Herman is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.